Repligen Corp (NAS:RGEN)
$ 166.895 -4.885 (-2.84%) Market Cap: 9.33 Bil Enterprise Value: 9.56 Bil PE Ratio: 667.58 PB Ratio: 4.73 GF Score: 93/100

Repligen Corp at Stephens Investment Conference Transcript

Nov 17, 2022 / 07:00PM GMT
Release Date Price: $174.69 (-8.52%)
Jacob K. Johnson
Stephens Inc., Research Division - MD & Analyst

All right. Good afternoon, everybody. Welcome to day 3 of the Stephens 2022 Conference. I'm Jacob Johnson, life science tools and pharma services analyst here at Stephens. Thank you all for joining us. Really pleased to be joined by the Repligen team for another year. We have CFO, Jon Snodgres, and Steven Chehames from Investor Relations. It will be a fireside chat format. But Jon, I'll let you make any introductory comments you'd like to make, and then we'll jump into Q&A.

Jon K. Snodgres
Repligen Corporation - CFO

Sure. So just a couple of short comments here before I jump in, though. I just want to say how great it is to be here, so thanks for having us again. And also I want to say it's great to see some smiling faces in the flesh here in the room. So a pleasure to see everybody, and thanks for being here today.

Just wanted to jump in and say a few words about Repligen, and just kind of highlight one of the strategies we've been working on. It will be pretty indicative of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot